Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting
25 oct. 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
New data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24...
Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
12 oct. 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
05 oct. 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer
08 sept. 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
10 août 2021 07h05 HE
|
Finch Therapeutics Group, Inc.
Takeda to accelerate leadership role in advancing FIN-524/TAK-524 ulcerative colitis development programTopline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in...
Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program
10 août 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
Finch to transfer FIN-524 program to Takeda for clinical developmentFinch and Takeda to continue discovery efforts targeting Crohn’s disease SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE)...
Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes
28 juin 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics to Present at Upcoming Virtual Investor Conferences
28 mai 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
13 mai 2021 07h00 HE
|
Finch Therapeutics Group, Inc.
Completed upsized IPO, raising $130.8 million in gross proceedsTopline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in PRISM-EXT expected in H2...